Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen
To determine whether neoadjuvant gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete response (pCR) for patients with muscle-invasive bladder cancer (MIBC) with secondary analyses of pathological downstaging and toxicity.
Source: Urology - Category: Urology & Nephrology Authors: Corbin J. Eule, Adam Warren, Elizabeth Molina Kuna, Eryn B. Callihan, Simon P. Kim, Thomas W. Flaig Source Type: research